Research : Molecular Epidemiology of Inflammatory Bowel Disease (IBD)
|  |
![]()
Hypothesis and Specific Aims
This is a prospective case control study
involving longitudinal assessment of biomarkers of genetic damage in
relation to disease activity and specific therapies (Aim 1), folate
deficiency and effect of repletion (Aim 2), and urinary phenol
excretion before and one month after initiating therapy for active
inflammatory bowel disease (IBD) (Aim 3). The following hypotheses will
be tested:
- Markers of Cytogenetics damage will be increased in patients with
IBD as compared to healthy controls, and level will decrease with
effective treatment of IBD.
- Cytogenetics damage will be increased in newly diagnosed or
relapsing subjects with IBD, not receiving folate supplementation, as
compared to healthy controls and will be reduced by folate
supplementation.
- Urinary phenol levels will be increased in patients with IBD as
compared to healthy controls and will correlate with disease activity
index.
These hypotheses will be tested through the following specific aims:
- Determine the relationship of IBD disease activity and standard
therapy to the generation of Cytogenetics markers in pediatric patients
in order to elucidate possible mechanisms of cancer induction.
- Define the role of folate deficiency and methylenetetrahydrofolate
reductase (MTHFR) polymorphisms on the generation of Cytogenetics
markers of genetic damage in pediatric patients with IBD and determine
whether folate supplementation can reduce levels of Cytogenetics
markers.
- Examine the relationship between urinary phenol levels, disease
activity, and the generation of markers of genetic damage to suggest
whether phenol may serve as a marker of IBD disease activity and
whether elevated phenol levels are possible contributors to the
generation of genetic damage.
Background and Significance
Inflammatory Bowel Diseaase (IBD), characterized
by acute and chronic inflammation of the bowel, includes two primary
diagnoses: Crohn's disease (CD) and ulcerative colitis (UC). Both
types of IBD have major similarities, including inflammatory infiltrates
in the gastrointestinal tract, folate deficiency, and increased
risk of cancer. The prevalence of IBD varies by study and by country.
Typical frequencies range between 12 and 40 per 100,000. The risk
of colorectal cancer in patients with IBD is increased 4 to 20-fold
compared to the general population, and some malignancies can develop
in apparently uninvolved sites. Patients with UC and CD have been
reported to develop leukemia, suggesting a potential relationship
between IBD and leukemia. While the pathological mechanism of IBD
remains unsolved, one typical characteristic of patients with IBD
is folate deficiency. Moreover, one of the primary therapies for
IBD is sulfasalazine (SASP), which also increases the risk of folate
deficiency. Finally, a recent study noted reduced red blood cell
folate levels in patients with UC and colorectal cancer compared
with a control group that did not have colorectal cancer.
Folate deficiency has been studied within
a number of populations. A recent study of folate intake among preschool
children suggested that 60% consumed less than the RDA. Blount,
et al, recently showed that in folate deficiency, synthesis of thymidylic
acid from dUMP, its precursor, was inhibited, causing dUMP to accumulate
in the cell. This condition increases the chance of misincorporation
of uracil into DNA in place of thymidine. When the DNA repair system
removes the uracil, it causes breaks in both DNA and chromosomes.
In a group of folate deficient volunteers, misincorporation of uracil
into DNA and an increased frequency of micronucleated erythrocytes,
presumably resulting from chromosome breaks, were observed. Thus,
uracil misincorporation has been suggested as an important consequence
of folate deficiency.
Folate supplementation is recommended for
IBD patients on SASP to compensate for potential folate deficiency,
but adequacy or consistency of the treatment is poorly evaluated.
Hanauer has reported that folate levels can be normalized in about
80% of adult patients supplemented with folic acid. However, data
pertaining to the effects of supplementation of pediatric patients
are lacking. Additionally, little data are available on the molecular
or Cytogenetics effects of folate deficiency or SASP treatment or
the effects of folate supplementation in any IBD patients. Only
one recent report notes increased Cytogenetics damage in adults
with CD compared with controls. A possible explanation is that oxidative
damage ensues, caused by altered characteristics of inflamed mucosa
and generation of oxygen-derived free radicals by phagocytic cells.
The impact of folate deficiency, which could potentially increase
both oxidative damage and uracil misincorporation, was not investigated.
MTHFR, an important enzyme in folate metabolism,
reduces the N5, N10 - methylenetetrahydrofolate into 5-methyltetrahydrofolate.
N5, N10 - methylenetetrahydrofolate is a folate metabolite that
methylates dUMP into dTMP. Increased levels of N5, N10 - methylenetetrahydrofolate,
related to decreased MTHFR activity might reduce uracil misincorporation
into DNA by decreasing the cellular dUMP/dTMP ratio. Conversely,
patients with normal MTHFR activity would demonstrate increased
uracil misincorporation and are potentially at increased risk for
cancer. Recently, a recessive polymorphism (677 C->T alanine to
valine) was identified in the MTHFR gene. This polymorphic allele
is common: 40% of a group of male American physicians screened were
found to have C/T heterozygous genotype, while 15% were C/C homozygous.
Since this genetic polymorphism can decrease the MTHFR enzymatic
activity, persons homozygous for this polymorphism will are less
likely to misincorporate uracil into their DNA, and thus have a
decreased background frequency of MN (a measure of DNA strand breakage)
and decreased cancer risk. As part of this project, we will explore
an association of MTHFR genetic polymorphism and IBD as reported
by Mahmud et al and risk of leukemia or colorectal cancer (elevated
biomarker of genetic damage ) in relation to MTHFR.
In summary we propose to initiate studies
of molecular and genetic damage in pediatric patients with IBD.
We will determine the relationship of markers of Cytogenetics damage
with disease activity, MTHFR polymorphisms, and with phenol and
folate levels.
Preliminary Studies
We have developed a procedure that improves
the MN assay in exfoliated cells by using fluorescent in situ hybridization
(FISH) with a pancentromeric probe. The main advantage of this approach
is that it allows for the mechanism of MN formation to be readily
identified. Micronucleus (MN) frequencies, estimated by the two
methods, are comparable. A significant 3-fold increase was observed
in the buccal cells of mortuary science students exposed to formaldehyde
using the new FISH-based technique, and the MN were found to be
primarily induced by chromosome breakage.
Preliminary data on exfoliated cells in
African-American children of Oakland demonstrate the feasibility
of collecting a sufficient number of samples for Cytogenetics analyses
not only from adults but also from children. More than 80% of samples
had more than 1000 scorable cells per slide, an adequate number
for effective analysis. Pilot analysis of the MN frequencies indicate
that inner-city African-American children tend to have variable
MN levels, including several individuals with rather high MN frequencies,
which may reflect either folate deficiency or environmental exposure
or both. Preliminary analysis of MN frequency in mononucleated and
binucleated lymphocytes from healthy children and adults suggests
a comparable level of Cytogenetics damage to that expected from
other studies.
Currently, analysis of Immunological Biomarkers and Genome Wide Association study are conducted in collaboration with Pediatric IBD Consortium. (make link)
| ![]() |
 |
Publications 
![]()
|
|
Holland N, Dong J, et al. Reduced Intracellular T-helper 1 Interferon-gamma in Blood of Newly-Diagnosed Children with Crohn's Disease and Age-related Changes in Th1/Th2 cytokine profiles.Pediatr Res.2008 Mar;63(3):257-62.
Holland N, Golden D, Hubbard A, Chen C, Huen K, Harmatz P, Heyman MB.
Cytogenetic damage in blood lymphocytes and exfoliated epithelial cells
of children with Inflammatory Bowel Disease. Pediatric Research. 2007 Feb;61(2):209-14.
M. Neri, D Ugolini, S Bonassi, A Fucic, N Holland, LE Knudsen, R J Sram, M Ceppi,V. Bocchini, DF Merlo.Children’s exposure to environmental pollutants and biomarkers of genetic damage: I Overview and critical issues. Mutation Research Reviews, 612:1-13, 2006.
Holland NT, Pfleger LP, Berger E, Ho A, Bastaki M. Molecular
Epidemiology Biomarkers - Sample Collection and Banking Considerations.
Toxicology and Applied Pharmacology, 206:261-68, 2005.
Holland NT, Smith MT, Eskenazi B,
Bastaki M. "Biological sample collecion and processing for
molecular epidemiological studies", Mutation Research
Reviews, 534, 217-34, 2003.
|
|
![]()
 |
|
|
|
|